PatrickSEllsworthMD

Hematology • Chapel Hill, NC

Clotting Disorder, Hemophilia & Bleeding Disorder, Sickle Cell & Other Anemias

Physician

Join to view full profile

Dr. Ellsworth is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ellsworth's full profile

Already have an account?

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 984-974-1000

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2017 - 2020
University of North Carolina HospitalsFellowship, Pediatric Hematology/Oncology, 2016 - 2020
University of RochesterResidency, Internal Medicine/Pediatrics, 2012 - 2016
Ohio State University College of MedicineClass of 2012

Certifications & Licensure

NC State Medical License 2016 - 2025
NY State Medical License 2015 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Pediatrics Pediatrics

Publications & Presentations

PubMed

Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort.
Jacqueline N Poston, Cassandra Bryan, Annette von Drygalski, Kadhim Al Banaa, Jenny Y Zhou
Blood Advances. 2024-11-26
1 citations
Hypertonicity and/or acidosis induce marked rheological changes under hypoxic conditions in sickle trait red blood cells.
Patrick Ellsworth, Izabela J Pawlinski, Rachel Sielaty, Anton Ilich, Yuriy Prokopenko
British Journal of Haematology. 2024-10-01
2 citations
Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event ...
Callie Berkowitz, Samuel Wilson, Nigel S Key, Patrick Ellsworth
Journal of Thrombosis and Haemostasis. 2024-09-01

Lectures

Recombinant Porcine Factor VIII Use in Bleed Treatment in Non-Severe Hemophilia a Inhibitor Patients: Dosing Strategies and Efficacy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Difference Between Revisions of "User:PackyShane"January 19th, 2017